Tadalafil Tablet
Product Images NDC 68071-3601

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3601). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3601 3)

This is a pharmaceutical label for Tadalafil 10mg tablets. It provides information on the manufacturer, lot number, expiration date, and a warning about the product. Customers are advised to consult a doctor for medical advice and to report any side effects to the FDA. The product should be stored at a controlled temperature of 68-77°F and kept out of reach of children.*

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

This text appears to list measurements for standing and supine Diastolic BP, as well as standing and supine Systolic BP. The data is likely recorded over time in hours.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

Not available.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

The text mentions a study involving the administration of different doses of tadalafil (a medication used to treat erectile dysfunction) and doxazosin (a medication used to treat high blood pressure). The study recorded systolic blood pressure at different time points after administration of the medications. This information could be helpful in understanding the effects of these medications on blood pressure.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

This text appears to be related to a study or evaluation comparing the IPSS total score between Tadalafil tablets 5 mg and a placebo over a duration of treatment of 12 weeks. The observed change from baseline shows significance with *p<0.01. The graph visualizes the scores at different time points (0, 4, 8, and 12 weeks) during the treatment.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

This text references a study comparing Tadalafil tablets of 5mg against a placebo. The statistical significance level is indicated as p<0.01. The graph or chart shows the duration of treatment in weeks, possibly comparing the effects of the medication over time.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.